Expertise in
19
conditions

Jianfeng N. Zhou

1095 Jiefang Avenue, 
Wuhan, CN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
19
conditions
1095 Jiefang Avenue, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Jianfeng Zhou practices in Wuhan, China. Zhou is highly rated in 19 conditions, according to our data. Their top areas of expertise are Leukemia, B-Cell Lymphoma, Hemophagocytic Lymphohistiocytosis, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 386 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

1095 Jiefang Avenue, Wuhan, China
Other Locations
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
No.72 Guangzhou Road, Nanjing, 210000, China
NO.1095 Jie Fang Avenue, Wuhan, 430030, China
1095# Jiefang Ave, Wuhan, 430030, China
No. 28 Fuxing Road, Beijing, 100853, China
NO. 1095, Jiefang Road, Wuhan, 430030, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: CAR-T (CAR-GPRC5D)
Study Phase: Phase 1
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Recruiting
Publish Date: July 31, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 1
Phase I Clinical Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in the Treatment of Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
Phase I Clinical Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in the Treatment of Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug
Study Drugs: Selinexor, CT103A
Study Phase: Phase 1
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Completed
Publish Date: March 18, 2022
Intervention Type: Biological
Study Drug: pCAR-19B cells
Study Phase: Phase 1
View 6 Less Clinical Trials

385 Total Publications

Expression of Concern: Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma.
Expression of Concern: Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile